reMYND’s efforts will be focused on reducing the gap between Alzheimer preclinical and clinical studies by improving the predictive power of AD animal models. Anticipating on the challenging translational step from preclinical to clinical testing in drug development, recent discoveries in human AD biomarker research will constitute the basis for selecting comparable disease read-outs and markers in the animal models.

Such (set of) biomarkers will allow for a better mapping of the correlation between pathological changes seen in animal models at different ages and the described disease progression in patients.

Dick Terwel, Study Director at reMYND’s CRO said:

"Considering the recent failure of large clinical trials for new AD therapies, increasing the translational predictability of animal models is one of the most urgent needs in the field. We are very excited about being a founding part of this prestigious network and as such getting access to both the resources and multidisciplinary expertise for carrying out the envisaged work".